Efficacy of Etanercept in the Treatment of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.
Cutis
; 107(6): E22-E28, 2021 Jun.
Article
em En
| MEDLINE
| ID: mdl-34314327
ABSTRACT
It has been suggested that the use of etanercept for treatment of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) might provide improved mortality benefit and decreased skin healing times. This retrospective study compared the use of single-dose subcutaneous etanercept to intravenous immunoglobulin (IVIG) and supportive care alone. Thirteen patients were treated with a single dose (50 mg) of subcutaneous etanercept. Results of this study support the use of etanercept as a potentially beneficial agent in the treatment of SJS/TEN.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Síndrome de Stevens-Johnson
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article